Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 3 of 3 results for avapritinib

  1. Avapritinib for treating advanced systemic mastocytosis (TA1012)

    Evidence-based recommendations on avapritinib (Ayvakyt) for treating advanced systemic mastocytosis in adults.

    Technology appraisal guidance
    Published
    6 November 2024
    View recommendations

    Sections for TA1012

  2. Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]

    In development Reference number: GID-TA11772 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  3. Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal) (TA730)

    NICE is unable to make a recommendation on avapritinib (Ayvakit) for treating unresectable or metastatic gastrointestinal stromal tumours in adults. Blueprint Medicines will not be launching the technology in the UK and has confirmed it will withdraw its submission.

    Technology appraisal guidance
    Published
    29 September 2021

    Sections for TA730